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Cost-EffECtivENEss EvaluatioN of BrENtuximaB vEdotiN for 
rEfraCtory/rElaPsEd HodgkiN lymPHoma: a ComParativE aNalysis of 
tHE rEsults of mExiCo aNd vENEzuEla
Meza-Torres B.1, Gay J.G.1, Jakouloff D.E.2
1Ti Salud, Mexico City, Mexico, 2Takeda Pharmaceuticals, Zurich, Switzerland
Objectives: Brentuximab vedotin is an orphan drug currently indicated for treat-
ment of patients with refractory/relapsed hodgkin lymphoma CD30+ following 
prior Auto Stem Cell Transplant (ASCT) or following two prior chemotherapy regi-
mens. This is a group of patients with a reported median survival of 12 months, 
with no defined standard of care and for whom clinical trials are single armed 
due to lack of appropriate comparators and scarcity of patients. Hence, an indirect 
comparison was performed to determine the cost-effectiveness of brentuximab 
vedotin in different countries. MethOds: A three state Markov model was devel-
oped. Effectiveness of brentuximab vedotin was obtained from the clinical trial of 
Gopal 2012. Effectiveness for the control group was obtained from 3 clinical trials 
evaluating survival of post-ASCT patients where data was disaggregated based on 
the patients´ response to prior ASCT/chemotherapy. The assumption was that only 
patients with ASCT/chemotherapy failure would serve as controls. The treatments 
received by the control group were based on the review of Martinez 2013, where 
64% received chemotherapy, 29% AlloSCT and 8% AutoSCT. Simulations were run for 
the Mexican and Venezuelan contexts. Direct medical costs were obtained from the 
local public sectors and WHO-CHOICE. Results: For the base case scenario of both 
countries the ICERs (USD/LYG) were respectively $38,614.34 (Mex) and $57,854.07 
(Ven), which compares favorably against accepted ICERs in the orphan drugs field. 
In the univariate sensitivity analysis the model was mainly sensitive to the costs 
of brentuximab, AutoSCT and AlloSCT. cOnclusiOns: Brentuximab vedotin is a 
cost-effective alternative for both countries, especially in the space of orphan drugs. 
The low costs of AutoSCT and AlloSCT in Venezuela relative to its GDP were what 
mainly accounted for higher ICERs. Differences in chemotherapy usage and costs 
did not alter the model. As a limitation, local epidemiology was not accounted for 
due to lack of data.
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ECoNomiC EvaluEtioN of fulvEstraNt 500 mg (f500) vErsus origiNal 
NoNstEroidal aromatasE iNHiBitors iN PatiENt witH advaNCEd 
BrEast CaNsEr iN russia (2 liNE tHEraPy)
Krysanov I.1, Tyapkina M.2
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Objectives: to perform cost-effectiveness analysis fulvestrant 500mg (F500) 
for the treatment of ﬁrst progression or recurrence of advanced breast cancer 
in postmenopausal patients compared with anastrozole 1mg (ANAS1), letrozole 
2.5mg (LET2,5), exemestane 25mg (EXE25) and exemestane 25mg+everolimus 
10mg (EXE25+EVE10). MethOds: the data on efficacy and safety of 2-line hor-
monal therapy of breast cancer were derived from a network meta-analysis and 
clinical data publication for overall survival (OS), progression free survival (PFS) 
and serious adverse events (SAE). We considered the direct costs on second and 
third line hormonal therapy and resource utilization. Data on resource usage, 
were based on expert opinion and open sources. 1-way sensitivity analyses were 
conducted. Results: in terms of OS F500 (mean 23.33 month) was as effective as 
ANAS1 (22.12) and more effective than LET2.5 (17.44) and EXE25 (18.31). The high-
est incremental cost-effectiveness ratio (ICER) estimated for F500 versus ANAS1 
was 84,592 USD per year with incremental effectiveness 1.21 month. The lowest 
ICER estimated for F500 versus LET2.5 was 22,873 USD per year with incremen-
tal effectiveness 5.90 month. The ICER for F500 versus EXE25 was 25,890 USD 
per year. In terms of PFS EXE25+EVE10 was more effective and costly, than F500. 
The CER for F500 was 1,714 USD per year versus 4,215 USD for EXE25+EVE10. 
A series of one-way sensitivity analyses showed this result is robust to variations 
in costs of drugs, physician examination, and variation in costs associated with 
SAE. cOnclusiOns: the use of F500 is more effective than LET2.5 and EXE25, and 
at least as efficacious as ANAS1 in terms of OS among postmenopausal women 
with advanced breast cancer after failure on 1-line endocrine therapy. In terms of 
PFS F500 less efficacious than EXE25+EVE10, however substantially cheaper. From 
perspective of federal health care system, the cost of LYG for F500 is less than the 
willingness to pay threshold.
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Objectives: Cancer accounts for around 1.3 million deaths and € 50 billion in 
health care expenditure in the European Union. Balancing increasing treatment 
costs and prevalence will be increasingly difficult for governments to manage. 
Advances in immunotherapies provide hope for a cancer cure; however its cost 
might be out of reach for governments under current health economic evalua-
tion methods which will be the aim of this research. MethOds: The years of 
life lost (YLL) in the UK due to cancer were obtained from the Institute of Health 
Metrics and Evaluation (IHME) database and multiplied by the NICE cost effec-
tiveness threshold of £20,000 per Quality Added life Year (QALY), this gave a first 
estimate of the potential cost of a cancer cure that would be within an 
acceptable cost effectiveness threshold. This cost was then modified to take into 
account the quality of life (QoL) of the general population, QALY discounting, 
cancer onset age, and other demographics. YLL due to disability in cancer were 
not included in the calculation. Results: It is estimated that 32.4% of the total 
YLL per year in the UK (5,615,310) are a consequence of cancer. The cost of sav-
ing these YYL at £20,000 per QALY was estimated to be around £12 billion for all 
cancers per year, meaning an extra £425 in taxes would have to be generated 
Objectives: Standard treatment for localized prostate cancer is radical prosta-
tectomy (PE) or radiation therapy (RT) which frequently cause erectile dysfunction 
(ED) and incontinence (IC). As tumor progression often is slow, active surveil-
lance (AS) has been proposed as an alternative treatment strategy. This study 
compares the cost-effectiveness of the three treatment strategies in a German 
context. MethOds: Based on claims data of a German sickness fund we ana-
lyzed men diagnosed with prostate cancer (ICD-10 code C61) in 2008. Life years 
gained and complication rates of ED and IC as well as costs of inpatient and 
outpatient treatment, pharmaceuticals, physical therapy, medical aids and co-
payments were tracked for 2.5 years after the initial treatment. An excess-cost 
analysis was applied. Strategies were compared in an age-matched and comor-
bidity-adjusted approach. Results: The baseline study sample included 25,376 
individuals. Exclusion of metastases, other cancer diagnoses and treatment strate-
gies resulted in 910 men with PE, 292 with RT and 124 with AS. After matching 
107 men remained in the AS group and 214 each in the PE and RT groups with 
a mean age of 70 years. Risk of long-term ED (PE: 0.112, RT: 0.009, AS: 0.056) 
and IC (PE: 0.313, RT: 0.009, AS: 0.084) was highest in the PE group. Compared to 
RT and AS, PE was associated with more life years gained during the cause of the 
study. Due to high inpatient costs of the initial surgery PE had ca. € 11,000 higher 
total per capita costs than RT and AS. cOnclusiOns: The analysis indicates that 
PE is associated with better prognosis and higher overall costs compared to RT 
and AS. 2.5 years follow-up might, however, not be enough to detect prostate 
cancer-specific deaths.
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CritiCal rEviEw of Cost-EffECtivENEss aNalysEs (CEa) of PrEvENtioN 
stratEgiEs agaiNst disEasEs assoCiatEd witH HumaN PaPillomavirus 
(HPv) iNfECtioN
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Objectives: It is estimated that almost all cervical cancers are associated with 
HPV infection. In most industrialised countries, cervical screening and vaccina-
tion with a bivalent or quadrivalent vaccine are recommended to prevent the 
disease. The current study aimed to critically review the results of CEAs that have 
assessed the trade-off between screening and vaccination. MethOds: A system-
atic literature review was conducted in order to explore the cost-effectiveness 
of HPV vaccination strategies with or without different screening strategies 
within the geographical context of Western Europe, North America and Australia. 
Modelling approach, disease considered, vaccination/screening settings and 
costs were compared. Results: A total of 1,188 citations were identified and 
20 studies were included in the review. Heterogeneity was seen across studies 
in terms of modelling approach, disease and prevention strategies considered. 
Inclusion of more HPV-related diseases significantly improves cost-effectiveness. 
The strategies combining screening and vaccination were found to be cost-effec-
tive when compared to vaccination or screening alone. In terms of screening 
strategy, HPV DNA testing with cytological triage showed a trend to be the opti-
mal strategy in vaccinated girls. However the gain in benefits reduced as the 
interval between screenings is reduced. Delaying the starting age of screening 
could be cost saving, with a limited increase in risk of cancer. An increasing vac-
cine valence seemed to counterbalance the detrimental effect of delayed/less 
frequent screening while the total costs of cervical disease prevention/treatment 
may be maintained or decreased. Lastly, vaccine price seemed to affect the incre-
mental cost-effectiveness ratio proportionally. cOnclusiOns: Despite hetero-
geneity in methodology across studies, similar trend of cost-effectiveness of 
competing prevention strategies was witnessed. In light of the trial results of the 
new nonavalent HPV vaccine, which provides protection against five additional 
types of the virus, the optimal prevention strategy needs to be reassessed within 
local context.
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mEtastatiC BrEast CaNCEr iN sECoNd-liNE CHEmotHEraPy
Krysanov I.1, Krysanova V.2
1Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, 
2I. M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To conduct a pharmacoeconomic evaluation of the application of ful-
vestrant compared with docetaxel and paclitaxel in the treatment of metastatic 
breast cancer in second-line chemotherapy. MethOds: Literature review of clinical 
effectiveness and safety of use of fulvestrant was conducted. Assess of the quality 
of research and level of evidence obtained in these results was performed. Direct 
medical costs consisted of the cost of the drug, the cost of patient management and 
correction of side effects. Duration of therapy, its effectiveness and side effects were 
obtained from relevant studies on clinical effectiveness (CONFIRM 2013, S. Jones et 
al. 2005). The cost of certain hematologic side effects have been taken from the study 
Belousov DU et al, 2012. To estimate the duration of hospital stay in the development 
of not hematological side effects, conducted a survey of experts. After calculating 
the total medical costs on compared regimens was conducted cost - effectiveness 
analysis with the calculation of CER. ResultsAccording to studies CONFIRM, 2013 
and S. Jones et al. 2005., in patients taking fulvestrant PFS and OS were to 6.5 and 
26.4 months, docetaxel - 5,7 and 15.4 months, paclitaxel - 3,6 and 12.7 months. The 
total cost of treatment were maximal for the docetaxel - 17685 USD, significantly 
lower for fulvestrant - 11803 USD and the minimal for paclitaxel - 7205 USD Cost-
effectiveness analysis showed that in spite of the average cost of treatment, taking 
into account its effectiveness in PFS and OS, the best CER was shown for fulves-
trant, followed by paclitaxel and docetaxel. The sensitivity analysis showed that 
the simulation results are resistant to increase of the prices for fulvestrant i up to 
12%. cOnclusiOns: The use of fulvestrant for the treatment of metastatic breast 
cancer in second-line chemotherapy is more cost effective than the appointment 
of docetaxel and paclitaxel.
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Medline, PubMed, and EMBASE to identify full economic evaluations that com-
pared different treatment strategies in postmenopausal women with primary 
breast cancer. Quality and modelling methodologies of included studies were 
assessed and summarised. Results: All the 31 included studies assessed surgery 
and none assessed PET as the initial treatment. Most included economic stud-
ies used a Markov model with life-time horizon and 1-year cycle length. Nine 
studies which included sub-group analysis for older women (over 65 years old) 
used similar economic models and transition states with younger women (50 
to 65 years old). The key disease-related health states were disease-free, recur-
rence, and death. Recurrence was mostly separated into loco-regional and distant 
recurrence. cOnclusiOns: This systematic review can inform the design of an 
economic model comparing PET with surgery as initial treatment in older women 
based on the following assumptions: (1) health states are applicable across age 
groups; (2) transition states for modelling surgery in the literature are transferable 
to model the same treatment for older women; (3) metastasis transition states 
including progression, progression-free, and death can be used to model the PET 
pathway. Future study will validate this model by using a longitudinal dataset of 
older women with primary breast cancer, and synthesize data from different data 
sources to populate this economic model.
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Cost EffECtivENEss of CEtuximaB iN 1st-liNE trEatmENt of ras wild-
tyPE mEtastatiC ColorECtal CaNCEr iN sCotlaNd: a summary of tHE 
suBmissioN to tHE sCottisH mEdiCiNEs CoNsortium
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Objectives: Colorectal cancer is the third most common cancer in Scotland, with 
nearly 4,000 cases reported in 2011 and 5.2% increase in incidence in the previous 
10 years. Recent studies have shown that a subgroup of metastatic colorectal cancer 
(mCRC) patients with wild-type (wt) RAS (KRAS and NRAS exons 2,3, 4) expressing 
tumours are likely to have enhanced response to anti-EGFR treatment compared 
to patients with mutant RAS exons (2,3, 4). RAS biomarkers aid identification of the 
patient group that is likely to benefit the most from anti-EGFR treatment such as 
cetuximab and therefore allow more efficient use of NHS Scotland resources. A New 
Product Assessment Form was submitted to the Scottish Medicines Consortium with 
the aim of demonstrating the latest improved outcomes in RAS wt mCRC patients 
(versus KRAS wt) treated with cetuximab in combination with chemotherapy and 
its cost effectiveness compared to currently available treatments. MethOds: 
A state-transition Markov cohort model was developed to simulate patient outcomes 
and costs for first and subsequent lines of treatment including the long-term sur-
vival after a successful curative resection of liver metastases. Results: The model 
estimated an incremental 0.28 life-years gained (LYG) with cetuximab + FOLFIRI 
compared to FOLFIRI alone and an incremental 0.32 LYG with cetuximab + FOLFOX 
compared to FOLFOX alone. The model was most sensitive to length of treatment 
with cetuximab. cOnclusiOns: The incremental cost effectiveness ratios imputed 
in the model are close to the traditional willingness to pay threshold adopted by 
the SMC. This analysis demonstrates that cetuximab in combination with FOLFIRI 
or FOLFOX in mCRC RAS wt patients is a cost-effective treatment compared with 
chemotherapy alone, specifically when taking into consideration that cetuximab 
qualifies as an end of life medicine (following SMC criteria) which raises the value 
of such intervention.
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Cost-EffECtivENEss aNalysis of BEvaCizumaB, fotEmustiNE 
aNd ExtENdEd-dosE tEmozolomidE iN PatiENts witH rECurrENt 
glioBlastoma iN sPaiN
Garcia Lopez J.L.1, Rodriguez Barrios J.M.2, Puig-Junoy J.2, Carrato Mena A.1
1Ramon Y Cajal University Hospital, Alcala University, Madrid, Spain, 2Pompeu Fabra University, 
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The treatment of glioblastoma after first-line treatment progression is not clearly 
established in Spain. Most accepted alternatives are nitrosoureas (fotemustine, F), 
extended-dose temozolomide (eT) or bevacizumab (B). Without clear standards of 
care, increased clinical and health policy uncertainty among decision makers should 
be clarified. So, economic evaluation might reduce those uncertainties. Objectives: 
To analyze the cost-effectiveness of bevacizumab, extended-dose temozolomide 
and fotemustine in patients with either recurrent or progressive glioblastoma after 
standard therapy, compared to standard clinical practice (SCP). MethOds: A cost-
effectiveness markov model was conducted from a payer perspective (time horizon 
1 year, 3%, discount rate, 2012, € ). Our model got three health states: alive without 
progression, alive with toxicity and progression as absorbing state. We subsequently 
performed a deterministic and probabilistic analysis of sensitivity. Main efficacy 
outcome was progression-free survival at six months (6m PFS). Toxicity data was 
based on relevant phase II studies. Health state utility values were estimated based 
on published values from an HTA report by Garside et al, 2007. Costs were obtained 
from a Spanish University Hospital. Results: Cost/effectiveness ratios were: SCP 
(based on carmustine) 2,368.45 € /year to obtain 6m PFS with stable health state 
utility value, F 4,112.97 € /year, B 15,122.49 € /year and eT 5,470.05 € /year. Incremental 
cost-effectiveness ratios were: F 7,404.12 € /year € /year to obtain 6m PFS with stable 
health state utility value, B 40,371.8 € /year and eT 45,853.51 € /year. Tornado diagram 
and CEAC showed our results robustness. cOnclusiOns: ICER analysis shows fote-
mustine to be the dominant option in the treatment of patients with recurrent or 
progressive glioblastoma.
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from each taxpayer. cOnclusiOns: A cancer cure evaluated under current health 
economic evaluation methods would cause a budget impact that would be 
unaffordable for governments due to the high prices that could be achieved 
while remaining cost effective. Although these types of technologies therapies 
are not currently available, payers might want to explore new methods of evalu-
ation, as exploring the possibility of calculating costs based on quality adjusted 
lifetimes rather than years or increasing discount rates on QALYs for immuno-
therapies.
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ECoNomiC imPaCt of tHE iNClusioN of PErtuzumaB for tHE trEatmENt 
of mEtastatiC BrEast CaNCEr HEr2 +
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Objectives: To analyze the economic impact of the incorporation of pertuzumab 
for the treatment of metastatic breast cancer HER2+ in a University Hospital accord-
ing to real data of our patients. MethOds: Cross-sectional study where the patients 
with breast cancer were analyzed in our hospital during one year (April 2013 to 
April 2014). The demographic data of the patients (age and weight) and antineo-
plastic treatments used were obtained from the computer program Hospiwin®. 
The dose and efficacy data have been obtained from the phase III CLEOPATRA trial. 
This clinical trial compares docetaxel + trastuzumab vs docetaxel + trastuzumab + 
pertuzumab with progression-free survival (PFS) 12.4 (CI 10.4-13.5) vs. 18.5 (CI 16.6-
21.6) months respectively. Costs of the drugs were included in the economic model 
developed in Excel® data base. The time horizon was one year and the perspective 
of medical leadership of the hospital was used. Results: During the study period 
371 patients were treated for breast cancer and 75 patients (20.2 %) were HER2+. The 
mean weight of 71.5 kg (SD = 17.1) and men BMI of 29.3 were obtained. The annual 
cost of docetaxel + trastuzumab + pertuzumab was 69,245.32 € vs 29,837.4 € (CI (in 
the docetaxel + trastuzumab treatment group. The cost per PFS per year was 44,964 
€ (CI 38,469-50,177 € ) in the docetaxel + trastuzumab + pertuzumab group vs 29,837 
(CI 26,640-35,948 € ) in the docetaxel + trastuzumab treatment group. The incremen-
tal cost effectiveness ratio (ICER) was 15.127 € /PFS per year. cOnclusiOns: The 
addition of pertuzumab to treatment with docetaxel / trastuzumab for metastatic 
breast cancer has shown an increase in SLP. However, the economic impact of this 
new drug, requires careful selection of patients who could benefit. Health authori-
ties will have to consider whether pertuzumab is cost-effective in terms of their 
willgness to pay.
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Objectives: Multitargeted receptor tyrosine kinase inhibitors are more effec-
tive alternatives to interferon-α and monoclonal antibodies in patients with 
metastatic renal cell carcinoma (mRCC). However, studies on the economic and 
humanistic outcomes associated with these treatments are sparse in the Chinese 
setting. This study evaluated the clinical and economic consequences of sunitinib 
compared with sorafenib and interferon-α from the third-party payer’s perspective 
in China. MethOds: A Markov model was developed to simulate disease progres-
sion and determine cost and outcomes over patient’s lifetime. The time horizon 
of analysis was patients’ lifetime with a maximum of five years in cycles of six 
weeks. The model was used to conduct a cost-utility analysis on sunitinib compared 
to interferon-α and sorafinib. Costs of physician, anti-cancer medications, hospi-
talization, laboratory, and palliative care were estimated. Outcomes were meas-
ured in progression-free life years (PFLYs), life years (LYs) and quality-adjusted life 
years (QALYs). A 3.5% discount rate was applied to both costs and QALYs gained.  
Results: In the base case, the total cost of the sunitinib arm was RMB217,038.50, 
the progression-free life year was 1.57, life year was 2.55, and QALY was 1.70. The 
incremental cost per PFLY between sunitnib and IFN-α was –RMB78,562.10 and 
RMB 22,501.03 between sunitinib and sorafenib. The incremental cost per life year 
between sunitnib and IFN-α was –RMB168,633.00 and RMB 21,022.38 between suni-
tinib and sorafenib. The incremental cost per QALY between sunitnib and IFN-α was –
RMB184,825.00 and RMB 29,493.42 between sunitinib and sorafenib. cOnclusiOns: 
This economic study used the final clinical results of the pivotal sunitinib trial that 
provides more accurate modeling results than previous studies based on extrapola-
tion. It was found that sunitinib was dominant compared to IFN-α . Sunitinib was 
cost effective compared to sorafenib based on the threshold recommended by the 
World Health Organization.
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aN EvidENCE-BasEd modEl dEsigN to iNform tHE Cost-EffECtivENEss 
EvaluatioN of Primary ENdoCriNE tHEraPy aNd surgEry for oldEr 
womEN witH Primary BrEast CaNCEr
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Objectives: Despite the lack of evidence-based information on their clinical and 
cost-effectiveness, surgery and primary endocrine therapy (PET) are the most 
commonly used initial treatment strategies for older women with primary breast 
cancer in the United Kingdom (UK). To evaluate the cost-effectiveness of PET and 
surgery, a decision analytical modelling is necessary. This systematic review aimed 
to summarise the modelling methodologies from the literature to inform the 
model design in older women. MethOds: An electronic database search was 
conducted using NHS Economic Evaluation Database, Cochrane Library, Ovid 
